Fresenius Medical Care AG and Co. KGaA (FMS) |
| 24.45 0.43 (1.79%) 07-13 16:00 |
| Open: | 24.22 |
| High: | 24.55 |
| Low: | 24.18 |
| Volume: | 450,069 |
| Market Cap: | 13,133(M) |
| PE Ratio: | 9.7 |
| Exchange: | New York Stock Exchange |
| Industry: | Medical - Care Facilities |
| Sector: | Healthcare |
| Technical analysis | ||||
![]() |
||||
| sell | buy | |||
| Resistance 2: | 28.67 |
| Resistance 1: | 24.55 |
| Pivot price: | 23.55 |
| Support 1: | 22.80 |
| Support 2: | 21.72 |
| 52w High: | 27.64 |
| 52w Low: | 20.02 |
Fresenius Medical Care AG & Co. KGaA specializes in comprehensive kidney dialysis treatment and associated services, operating across Germany, North America, and numerous international territories. Through an extensive network of outpatient clinics, it delivers essential dialysis therapy along with laboratory and diagnostic support. For home-based care, the company supplies necessary equipment, provides comprehensive training, and offers ongoing patient assistance, including clinical oversight and coordinating supply deliveries directly to patients. In the United States, Fresenius Medical Care also contracts with hospitals to provide vital dialysis interventions for hospitalized individuals suffering from end-stage renal disease (ESRD) and acute kidney failure. Beyond services, it is a prominent developer, manufacturer, and distributor of a broad range of dialysis products. This portfolio encompasses polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers and solutions, concentrates, bloodlines, renal pharmaceuticals, and water treatment systems. Additionally, the company produces non-dialysis medical devices, including acute cardiopulmonary and apheresis products. Its pharmaceutical division focuses on developing, acquiring, and in-licensing specialized renal medications, distributing these essential drugs and supplies to both individual patients' homes and dialysis centers. The company also extends its medical offerings to include a variety of specialized services such as vascular, cardiovascular, and endovascular care, operating ambulatory surgery centers for vascular procedures, and providing physician services in nephrology and cardiology. Products are sold directly to dialysis clinics, hospitals, and specialized treatment centers, complemented by sales through local teams, independent distributors, dealers, and agents. By February 23, 2022, Fresenius Medical Care managed an impressive network of 4,171 outpatient dialysis clinics across roughly 150 countries. Established in 1996, the company maintains its headquarters in Bad Homburg, Germany.
| EPS | 1.860 |
| Book Value | 27.950 |
| PEG Ratio | 0.86 |
| Gross Profit | 9.346 |
| Profit Margin (%) | 4.88 |
| Operating Margin (%) | 8.14 |
| Return on Assets (ttm) | 3.6 |
| Return on Equity (ttm) | 7.8 |
Mon, 13 Jul 2026
Reasons to retain Fresenius Medical stock in your portfolio for now - MSN
Sun, 12 Jul 2026
Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) Given Average Rating of "Reduce" by Brokerages - MarketBeat
Wed, 08 Jul 2026
Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now - TradingView
Mon, 06 Jul 2026
Fresenius Medical Care outlines its dialysis strategy. Long-term demand shapes FMS outlook - ad-hoc-news.de
Sun, 05 Jul 2026
Moran Wealth Management LLC Has $7.85 Million Holdings in Fresenius Medical Care AG & Co. KGaA $FMS - MarketBeat
Tue, 23 Jun 2026
DVA vs. FMS: Which Dialysis Leader Is Better Positioned Now? - TradingView
|
StockChart iOS |
StoxlineLite iOS |
StoxlineLite iOS |
OptionCalc iOS |
|
StockChart Android |
StoxlineLite Android |
StoxlinePro Android |
OptionCalc Android |